SCHEMBL5871423

SCHEMBL5871423

Cc1ccc2c(O)cc(=O)n(Cc3ccccc3)c2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.58
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
ALDH1A1 P00352 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
MAPT P10636 1/20 0.58
HPGD P15428 3/20 0.53
HTT P42858 2/20 0.53
LMNA P02545 2/20 0.53
GAA P10253 1/20 0.53
BCL2 P10415 1/20 0.48
MCL1 Q07820 1/20 0.48
ADORA1 P30542 1/20 0.48
PSMD14 O00487 1/20 0.47
TSHR P16473 1/20 0.47
SRC P12931 2/20 0.47
CASR P41180 1/20 0.46
ATM Q13315 1/20 0.46
TLR7 Q9NYK1 1/20 0.44
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11493070 0.84 ADORA1 (0.53) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL829931 0.80 MEN1 (0.63) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL11253837 0.78 ALDH1A1 (0.43) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4185653 0.78 MAT2A (0.56) KDM4EKMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL3521617 0.76 ALDH1A1 (0.51) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL11488105 0.75 CNR1 (0.47) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1522428 0.74 ADORA1 (0.46) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL8358470 0.74 KMT2A (0.72) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL9266145 0.74 ATM (0.77) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1523842 0.74 ALDH1A1 (1.00) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 KDM4E 4050/4885MEN1 3746/4885KMT2A 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.